Damage to Liver Function after TACE of Anticancer Drugs in Hepatocellular Carcinoma:Evaluation of Two Kinds of Anticancer Drugs
- Author:
Wei LU
;
Yanhao LI
;
Zhijian YU
;
Xiaofeng HE
;
Yong CHEN
;
Jianbo ZHAO
- Publication Type:Journal Article
- Keywords:
Carcinoma;
Hepatocellular chemoembolization;
Therapeutic liver function
- From:
Journal of Interventional Radiology
2006;15(6):351-355
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the damage of liver function after transcatheter arterial chemoembolization (TACE) with low-dose versus conventional-dose anticancer drugs in patients with hepatocellular carcinoma (HCC). Methods One hundred and twelve patients with unresectable HCC were randomly divided into two groups (A and B) to receive superselective TACE. Low-dose anticancer drugs including mitomycin C (MMC) 2 ～ 8 mg, epirubicin (EPI) 5 ～ 10 mg and carboplatin (CBP) 100 mg were used in group A (n= 52), and conventional-dose of anticancer drugs (MMC 10 mg, EPI 40 mg and CBP 300 mg)for patients in group B(n= 60). Lipiodol-anticancer drugs emulsion was injected into the feeding arteries of tumor and then followed by embolization of gelatin sponge (GS) or polyvinyl alcohol (PVA) particles.Laboratory examination of the liver function including Child-Pugh scores, total bilirubin (TBIL), albumin (ALB) and alanine aminotransferase (ALT) were evaluated respectively before TACE and at third day, one week and four weeks after this procedure. Results In both groups, TBIL, ALT, and Child-Pugh scores increased (P ＜ 0.001 or P ＜ 0.05) and ALB decreased (P ＜ 0.001 or P ＜ 0.01) at three days and one week after TACE. Four weeks after-procedure, all the parameters described above showed no significant difference than those before the procedure in group A (P ＞ 0.05 ). On the contrary in group B, a significant difference (P ＜ 0.05) was found in the comparison of these parameters (except ALT). Conclusion Superselective TACE with low-dose anticancer drugs may induce transient impairment of liver function in the patients with HCC, but those patients used conventional-dose of anticancer drugs frequently cause lasting and more serious worsening of liver function.
